par Picard, Odile;Bernard, Jacky;Lachgar, Abderrahim;Fall, LS;Achour, Ammar;Mbika, JP;Zagury, Jean-François;Zagury, Daniel;Carlotti, M.;Bizzini, Bernard;Carelli, Claude;Salaun, JJ;Lurhuma, Zirimwabagangabo;Desgranges, Claude;Boyer, Véronique;Burny, Arsène 
Référence Biomedicine & pharmacotherapy, 46, 8, page (353-357)
Publication Publié, 1992
Référence Biomedicine & pharmacotherapy, 46, 8, page (353-357)
Publication Publié, 1992
Article révisé par les pairs
| Résumé : | In the first AIDS vaccine trial, immunizing preparations were based on HIV-1 Env protein (gp160). Immunogenic properties of gp160 which trigger both a humoral and cellular immune response have since justified its use in various vaccine programs, both past and present. Many reports however have underlined deleterious effects on the immune system - anti-HIV-1 enhanced antibodies, anti-CD4 autoantibodies, and inhibition of T cell activation by HIV-1 - particularly associated with the Env protein. The present study shows that gp160 presented in a biologically inactivated but immunogenic form, as used in our trial, could avoid these complications. Bio-hazards associated with gp0000 which indeed could be removed by appropriate treatment of the native protein, should be taken into consideration in AIDS vaccine programs. anti-AIDS vaccine / HIV-1 Env gp160 protein enhancing antibodies / anti-CD4 autoantibodies. © 1992. |
